Jonathan Fleming has been creating, financing, and managing innovative life science companies for 35 years in the USA, Europe, Asia, and Israel. Currently, he serves as the Executive Chairman of QurAlis Inc. and Enclear Therapies, two companies focused on ALS precision medicine, as well as Aquaculture Research Corp. He is a board director of several other private biotechnology companies, including Q-State Biosciences, SQZ Biotech, and Continuus Pharmaceuticals.
Since 2002, Mr. Fleming has been a senior lecturer at the MIT Sloan School of Management, where he co-teaches a graduate-level course on strategy for life science companies. Before his current roles, Mr. Fleming was the Managing Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science investments, which raised over $1 billion in early-stage capital, resulting in 21 IPOs and over 40 M&A transactions. Mr. Fleming has helped co-found numerous companies, including Synaptic Pharmaceuticals (acquired by Lundbeck), Memory Pharmaceuticals (acquired by Roche), and Hypnion Pharmaceuticals (acquired by Eli Lilly).
During his career, Mr. Fleming has held leadership roles on the boards of numerous public companies. Since 2006, he has served on the executive board of NEHI, a healthcare policy think tank based in Cambridge, MA. He holds a Master’s degree in Public Administration from Princeton University’s Woodrow Wilson School of Public and International Affairs, and a Bachelor’s degree in Political Science from the University of California, Berkeley.